197 related articles for article (PubMed ID: 10607246)
1. Evaluation of twice-daily administration of interferon-beta for chronic hepatitis C.
Kakizaki S; Takagi H; Yamada T; Ichikawa T; Abe T; Sohara N; Kosone T; Kaneko M; Takezawa J; Takayama H; Nagamine T; Mori M
J Viral Hepat; 1999 Jul; 6(4):315-9. PubMed ID: 10607246
[TBL] [Abstract][Full Text] [Related]
2. High sustained response to daily dosing of interferon with ribavirin in chronic hepatitis C patients naïve to therapy.
Abbas Z; Hamid S; Tabassum S
J Gastroenterol Hepatol; 2002 May; 17(5):577-81. PubMed ID: 12084032
[TBL] [Abstract][Full Text] [Related]
3. Different turnover rate of hepatitis C virus clearance by different treatment regimen using interferon-beta.
Shiratori Y; Perelson AS; Weinberger L; Imazeki F; Yokosuka O; Nakata R; Ihori M; Hirota K; Ono N; Kuroda H; Motojima T; Nishigaki M; Omata M
J Hepatol; 2000 Aug; 33(2):313-22. PubMed ID: 10952250
[TBL] [Abstract][Full Text] [Related]
4. Twice-daily administration of interferon-beta for chronic hepatitis C is not superior to a once-daily regimen.
Suzuki F; Chayama K; Tsubota A; Akuta N; Someya T; Kobayashi M; Suzuki Y; Saitoh S; Arase Y; Ikeda K; Kumada H
J Gastroenterol; 2001 Apr; 36(4):242-7. PubMed ID: 11324727
[TBL] [Abstract][Full Text] [Related]
5. A potent antiviral effect on hepatitis C viral dynamics in serum and peripheral blood mononuclear cells during combination therapy with high-dose daily interferon alfa plus ribavirin and intravenous twice-daily treatment with interferon beta.
Asahina Y; Izumi N; Uchihara M; Noguchi O; Tsuchiya K; Hamano K; Kanazawa N; Itakura J; Miyake S; Sakai T
Hepatology; 2001 Aug; 34(2):377-84. PubMed ID: 11481623
[TBL] [Abstract][Full Text] [Related]
6. Comparison of thrice weekly vs daily human leucocyte interferon-alpha therapy for chronic hepatitis C. TVVH Study Group.
Chemello L; Cavalletto L; Bernardinello E; Boccato S; Casarin P; Cavinato F; Urban F; Pontisso P; Cecchetto A; Gatta A; Alberti A
J Viral Hepat; 1999 Jul; 6(4):321-7. PubMed ID: 10607247
[TBL] [Abstract][Full Text] [Related]
7. Complete response to twice-a-day interferon-beta with standard interferon-alpha therapy in acute hepatitis C after a needle-stick.
Oketani M; Higashi T; Yamasaki N; Shinmyozu K; Osame M; Arima T
J Clin Gastroenterol; 1999 Jan; 28(1):49-51. PubMed ID: 9916668
[TBL] [Abstract][Full Text] [Related]
8. Differences between interferon-alpha and -beta treatment for patients with chronic hepatitis C virus infection.
Furusyo N; Hayashi J; Ohmiya M; Sawayama Y; Kawakami Y; Ariyama I; Kinukawa N; Kashiwagi S
Dig Dis Sci; 1999 Mar; 44(3):608-17. PubMed ID: 10080158
[TBL] [Abstract][Full Text] [Related]
9. Treatment with interferon-alpha2b of naive non-cirrhotic patients with chronic hepatitis C according to viraemia and genotype. Results of a randomized multicentre study. The North West Italian Hepatological Group.
Saracco G; Ciancio A; Ghisetti V; Rocca G; Cariti G; Andreoni M; Tabone M; Roffi L; Calleri G; Ballaré M; Terreni N; Sartori M; Tappero GF; Traverso A; Poggio A; Orani A; Maggi G; Di Napoli A; Arrigoni A; Rizzetto M;
Eur J Gastroenterol Hepatol; 2001 Feb; 13(2):149-55. PubMed ID: 11246614
[TBL] [Abstract][Full Text] [Related]
10. Lead-in treatment with interferon-β/ribavirin may modify the early hepatitis C virus dynamics in pegylated interferon alpha-2b/ribavirin combination for chronic hepatitis C patients with the IL28B minor genotype.
Itokawa N; Atsukawa M; Tsubota A; Kondo C; Hashimoto S; Fukuda T; Matsushita Y; Kidokoro H; Kobayashi T; Narahara Y; Nakatsuka K; Kanazawa H; Iwakiri K; Sakamoto C
J Gastroenterol Hepatol; 2013 Mar; 28(3):443-9. PubMed ID: 23173698
[TBL] [Abstract][Full Text] [Related]
11. Long-term lymphoblastoid interferon-alpha therapy for non-cirrhotic chronic hepatitis C: an Italian multicentre study on dose and duration of IFN alpha treatment.
Piccinino F; Felaco FM; Sagnelli E; Aprea L; Messina V; Pasquale G; Filippini P; Scolastico C
Res Virol; 1998; 149(5):283-91. PubMed ID: 9879606
[TBL] [Abstract][Full Text] [Related]
12. Early changes in hepatitis C virus (HCV) RNA levels predict response to interferon treatment in noncirrhotic HCV patients.
Fallows G; Kaita K; Minuk G; Penner F; Smart G; Dawood M; Rosser B
Can J Gastroenterol; 2000; 14 Suppl B():30B-35B. PubMed ID: 10938502
[TBL] [Abstract][Full Text] [Related]
13. Quantification of serum hepatitis C virus RNA with daily or standard interferon doses plus ribavirin in nonresponder patients with chronic hepatitis C.
Buti M; Olive G; Stalgis C; Esteban R; Guardi J
Dig Dis Sci; 2000 Apr; 45(4):685-9. PubMed ID: 10759235
[TBL] [Abstract][Full Text] [Related]
14. A short induction regimen of interferon-alpha is not effective for treatment of relapse in chronic hepatitis C: a randomized trial. For the multicentre GER-CYT-01 group.
Poynard T; Daurat V; Chevret S; Moussalli J; Degos F; Bailly F; Borotto E; Buffet C; Bartolomei-Portal I; Richardet JP; Riachi G; Calmus Y; Bréchot C; Vidaud M; Olivi M; Bedossa P; Riffaud PC; Chastang C
J Viral Hepat; 1999 Sep; 6(5):381-6. PubMed ID: 10607254
[TBL] [Abstract][Full Text] [Related]
15. Effect of in vitro interferon-beta administration on hepatitis C virus in peripheral blood mononuclear cells as a predictive marker of clinical response to interferon treatment for chronic hepatitis C.
Mochizuki K; Kagawa T; Takashimizu S; Kawazoe K; Kojima S; Nagata N; Nakano A; Nishizaki Y; Shiraishi K; Itakura M; Watanabe N; Mine T; Matsuzaki S
World J Gastroenterol; 2004 Mar; 10(5):733-6. PubMed ID: 14991949
[TBL] [Abstract][Full Text] [Related]
16. Prolonged negative HCV-RNA status led to a good outcome in chronic hepatitis C patients with genotype 1b and super-high viral load.
Kohno H; Aimitsu S; Kitamoto M; Aisaka Y; Kawakami H; Chayama K
Intervirology; 2006; 49(6):362-9. PubMed ID: 16926549
[TBL] [Abstract][Full Text] [Related]
17. Lymphoblastoid interferon alfa-n1 improves the long-term response to a 6-month course of treatment in chronic hepatitis C compared with recombinant interferon alfa-2b: results of an international randomized controlled trial. Clinical Advisory Group for the Hepatitis C Comparative Study.
Farrell GC; Bacon BR; Goldin RD
Hepatology; 1998 Apr; 27(4):1121-7. PubMed ID: 9537453
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of interferon dose and prediction of response in chronic hepatitis C: Benelux study in 336 patients.
Brouwer JT; Nevens F; Kleter B; Elewaut A; Adler M; Brenard R; Chamuleau RA; Michielsen PP; Pirotte J; Hautekeete ML; Weber J; Bourgeois N; Hansen BE; Bronkhorst CM; ten Kate FJ; Heijtink RA; Fevery J; Schalm SW
J Hepatol; 1998 Jun; 28(6):951-9. PubMed ID: 9672169
[TBL] [Abstract][Full Text] [Related]
19. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT).
Poynard T; Marcellin P; Lee SS; Niederau C; Minuk GS; Ideo G; Bain V; Heathcote J; Zeuzem S; Trepo C; Albrecht J
Lancet; 1998 Oct; 352(9138):1426-32. PubMed ID: 9807989
[TBL] [Abstract][Full Text] [Related]
20. Pilot study on the safety and efficacy of intravenous natural beta-interferon therapy in patients with chronic hepatitis C unresponsive to alpha-interferon.
Mazzoran L; Grassi G; Giacca M; Gerini U; Baracetti S; Fanni-Canelles M; Zorat F; Pozzato G
Ital J Gastroenterol Hepatol; 1997 Aug; 29(4):338-42. PubMed ID: 9476188
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
